Mepsevii (Vestronidase Alfa)

Vestronidase alfa is a recombinant form of human beta‑glucuronidase. After intravenous infusion, it is taken up by cells via mannose‑6‑phosphate receptors and delivered to lysosomes, where it hydrolyzes accumulated dermatan‑ and chondroitin‑sulfate glycosaminoglycans, thereby decreasing substrate storage and improving disease‑related symptoms.

The dosing regimen for Mepsevii is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, weight, and response to therapy. Healthcare professionals set the dose and infusion schedule according to current medical guidelines and patient needs.

Safety data for Mepsevii during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mepsevii. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Mepsevii is the only approved enzyme replacement therapy specifically targeting the beta‑glucuronidase deficiency in MPS VII. Alternative approaches, such as hematopoietic stem cell transplantation, aim to provide a source of functional enzyme but carry higher procedural risk. Mepsevii offers a targeted, systemic replacement of the missing enzyme with a well‑characterized safety profile.

Mepsevii must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and discoloration, and any deviation from the recommended temperature range should be reported.

Mepsevii is administered as an intravenous infusion. The infusion is typically given under medical supervision in a hospital or clinic setting, allowing healthcare professionals to monitor the patient for any infusion‑related reactions and to manage the rate of administration according to the prescribing information.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, significant hepatic enzyme elevations, and thrombocytopenia that may lead to bleeding complications. Patients should be closely monitored during and after infusion, and any signs of allergic reaction, liver dysfunction, or abnormal bleeding should prompt immediate medical evaluation.

Mepsevii should not be used in individuals with a known hypersensitivity to vestronidase alfa or any of its excipients. Caution is also advised for patients with uncontrolled infections, severe liver disease, or those receiving live attenuated vaccines, as these conditions may increase the risk of adverse outcomes.